Daiichi pays $225m to access gene therapy production platform

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Katy L. Pack)
(Image: Getty/Katy L. Pack)

Related tags: Daiichi sankyo, Ultragenyx, Gene therapy, AAV platform

Daiichi partners with Ultragenyx to utilize its HeLa producer cell line platform for commercial-scale gene therapy production.

In return for access to the adeno-associated virus (AAV) platform, Daiichi Sankyo was prepared to offer $200m (€185m) upfront to Ultragenyx.

The platform at the center of the deal is HeLa, a producer cell line platform that allows for the large commercial-scale production of gene therapies. Ultragenyx states that this platform is ‘more consistent’ and ‘less expensive’ in comparison to other gene therapy manufacturing platforms.

Also included in the deal is Ultragenyx’s proprietary HEK293 transient transfection system for AAV manufacture.

Daiichi will receive non-exclusive access to the technology for use in its internal gene therapy projects.

Once technology transfer is completed to Daiichi, the company will then pay an additional $25m. Ultragenyx will receive single-digit royalties on net sales of any Daiichi product manufactured by the technology.

Masayuki Yabuta, head of Daiichi Sankyo’s biologics division, said, “In order to provide these drugs to patients in the future, manufacturing technology must be established early. Ultragenyx's proprietary technology is particularly excellent in terms of stable quality, high production efficiency, and ability to accommodate mass production.”

According to Daiichi, the company is interested in the development of gene therapies for retinal diseases and rare diseases, as well as specifying​ that it has no interest in gene therapy to insert genetic material into the host genome.

Yabuta added that the company is currently doing discovery research in the gene therapy area, which Daiichi sees as offering long-term business potential once it completes its strategic plan moving toward 2025, marked by a shift towards the development and licensing of oncology-focused assets.

The agreement Ultragenyx has signed with Daiichi features the option for the former company to co-develop and co-commercialize any rare disease product at the investigational new drug stage.

Related news

Show more

Related products

show more

How Viral Safety Testing Will Evolve

How Viral Safety Testing Will Evolve

Viral Safety for mAb: Prevent, Detect, Remove | 20-May-2020 | Event Programme

The pressure to shorten delivery times and reduce costs for biologics are driving an evolution in the biomanufacturing space. Many of the methods used...

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Related suppliers

Follow us


View more